These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2034319)

  • 1. [Role of calcium carbonate in the treatment of renal osteodystrophy].
    Morinière P; Boudailliez B; Westeel PF; Achard JM; Djerad M; Nahle M; Amar M; Fournier A
    Nephrologie; 1991; 12(1):31-41. PubMed ID: 2034319
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effects of CaCO3 on renal osteodystrophy--comparison of patients with chronic renal failure in the predialytic stage and patients undergoing maintenance hemodialysis].
    Okada K; Kuno T; Yanai M; Maeda H; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1988 Aug; 30(8):1053-62. PubMed ID: 3244188
    [No Abstract]   [Full Text] [Related]  

  • 3. Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experience.
    Morinière P; Fournier A; Westeel PF; Idrissi A; Renaud H; Hocine C; Belbrik S; Marie A; Leflon P; Sebert JL
    Contrib Nephrol; 1988; 64():58-73. PubMed ID: 3053039
    [No Abstract]   [Full Text] [Related]  

  • 4. Technological testing of calcium carbonate tablets for use in the treatment of renal osteodystrophy.
    Dal Zotto M; Ragazzi E; Realdon N; Dalla Fini G
    Farmaco; 1993 Jul; 48(7):989-1005. PubMed ID: 8397681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is calcium carbonate a safe phosphate binder in children with chronic renal failure?
    Lal SM; Groshong T
    Int J Artif Organs; 1992 Aug; 15(8):499-501. PubMed ID: 1399100
    [No Abstract]   [Full Text] [Related]  

  • 6. Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3.
    Fournier A; Idrissi A; Sebert JL; Gueris J; Garabedian M; Renaud H; Westeel PF
    Kidney Int Suppl; 1988 Mar; 24():S178-9. PubMed ID: 3163044
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy.
    Watson AR; Kooh SW; Tam CS; Reilly BJ; Balfe JW; Vieth R
    Child Nephrol Urol; 1988-1989; 9(4):220-7. PubMed ID: 3255485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis.
    Meyrier A; Marsac J; Richet G
    Kidney Int; 1973 Aug; 4(2):146-53. PubMed ID: 4744972
    [No Abstract]   [Full Text] [Related]  

  • 9. The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
    Slatopolsky E
    Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of renal osteodystrophy: physiopathology and secondary effects].
    Haldimann B; Flury W
    Schweiz Med Wochenschr; 1977 Aug; 107(32):1113-8. PubMed ID: 333572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current treatment of renal osteodystrophy in children].
    Macher MA; Baudouin V; Akil R; Loirat C
    Arch Pediatr; 1997; 4(2 Suppl 2):91s-94s. PubMed ID: 9246312
    [No Abstract]   [Full Text] [Related]  

  • 13. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy?
    Ionova D; Zlatarska S; Kirjakov Z
    Nephrol Dial Transplant; 1995; 10(9):1782. PubMed ID: 8559512
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal osteodystrophy and its treatment.
    Duursma SA; Mees EJ
    Neth J Med; 1973; 16(2):101-7. PubMed ID: 4705764
    [No Abstract]   [Full Text] [Related]  

  • 15. The radiographic spectrum of renal osteodystrophy.
    Molpus WM; Pritchard RS; Walker CW; Fitzrandolph RL
    Am Fam Physician; 1991 Jan; 43(1):151-8. PubMed ID: 1986484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment and prevention of uremic osteodystrophy.
    Giovannetti S; Barsotti G; Gretz N; Kraft K
    Contrib Nephrol; 1989; 72():66-72. PubMed ID: 2743774
    [No Abstract]   [Full Text] [Related]  

  • 18. [Physiopathology of renal osteodystrophy. I. Patients with kidney failure without dialysis].
    Fournier A; Bordier P; Weil B; Safar M; Idatte JM
    Presse Med (1893); 1971 Oct; 79(45):2017-21. PubMed ID: 5119047
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
    Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitriol and calcium carbonate therapy in early chronic renal failure.
    Bianchi ML; Colantonio G; Campanini F; Rossi R; Valenti G; Ortolani S; Buccianti G
    Nephrol Dial Transplant; 1994; 9(11):1595-9. PubMed ID: 7870349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.